Search Results - "Devos, David"

Conservative iron chelation for VAC14: Two-year clinical-radiological follow-up.

Authors: Ollivier, Thomas Devos, David Kuchcinski, Gregory et al.

Source: Journal of Parkinson's Disease. Jun2025, Vol. 15 Issue 4, p925-928. 4p.

Therapeutic modalities of deferiprone in Parkinson's disease: SKY and EMBARK studies.

Authors: Devos, David Rascol, Olivier Meissner, Wassilios G et al.

Source: Journal of Parkinson's Disease. Feb2025, Vol. 15 Issue 1, p72-86. 15p.

Magnetic resonance imaging characterization of an α‐synuclein model of Parkinson's disease.

Authors: Katrib, Chirine Hladky, Hector Timmerman, Kelly et al.

Source: European Journal of Neuroscience. Dec2024, Vol. 60 Issue 12, p7038-7057. 20p.

Subjects: Magnetic resonance imaging, Functional magnetic resonance imaging, Laboratory rats, Parkinson's disease, Animal disease models

Iron on trial: recasting the role of iron in neurodegeneration.

Authors: Ayton, Scott Moreau, Caroline Devos, David et al.

Source: Brain: A Journal of Neurology; Dec2025, Vol. 148 Issue 12, p4241-4247, 7p

This result is not displayed to guests.
Login for full access.

LIBX‐A401: A Novel Selective Inhibitor of Acyl‐CoA Synthetase Long Chain Family Member 4 (ACSL4) and Its Binding Mode.

Authors: Mazhari Dorooee, Darius Ravez, Séverine Vertommen, Didier et al.

Source: Angewandte Chemie; 5/5/2025, Vol. 137 Issue 19, p1-10, 10p

Is TNF inhibitor exposure a risk factor for amyotrophic lateral sclerosis?

Authors: Petitpain, Nadine Devos, David Bagheri, Haleh et al.

Source: Fundamental & Clinical Pharmacology. Dec2019, Vol. 33 Issue 6, p689-694. 6p.

Behavioral and functional characterization of early-stage Parkinson's disease models reveals attentional deficits and circuit-level connectivity alterations.

Authors: Naïdji, Camille Devos, David Betrouni, Nacim et al.

Source: Experimental Neurology. Oct2026, Vol. 404, pN.PAG-N.PAG. 1p.

A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis.

Authors: Devos, David Moreau, Caroline Kyheng, Maeva et al.

Source: Scientific Reports. 2/27/2019, Vol. 9 Issue 1, p1-11. 11p.

Are Upper-Body Axial Symptoms a Feature of Early Parkinson’s Disease?

Authors: Moreau, Caroline Devos, David Baille, Guillaume et al.

Source: PLoS ONE. 21/9/2016, Vol. 11 Issue 9, p1-13. 13p.

Neuroprotective activity of a virus-safe nanofiltered human platelet lysate depleted of extracellular vesicles in Parkinson's disease and traumatic brain injury models.

Authors: Delila, Liling Nebie, Ouada Nhi Thao Ngoc Le et al.

Source: Bioengineering & Translational Medicine; Jan2023, Vol. 8 Issue 1, p1-15, 15p

Human platelet lysate biotherapy for traumatic brain injury: preclinical assessment.

Authors: Nebie, Ouada Carvalho, Kevin Barro, Lassina et al.

Source: Brain: A Journal of Neurology; Oct2021, Vol. 144 Issue 10, p3142-3158, 17p

Effect of intermittent theta-burst stimulation on akinesia and sensorimotor integration in patients with Parkinson's disease.

Authors: Degardin, Adrian Devos, David Defebvre, Luc et al.

Source: European Journal of Neuroscience. Sep2012, Vol. 36 Issue 5, p2669-2678. 10p. 1 Diagram, 3 Charts, 4 Graphs.

Subjects: Parkinson's disease, Transcranial magnetic stimulation, Sensorimotor integration, Dopamine, Dopa, Motor cortex, Afferent pathways

Dopaminergic and non-dopaminergic pharmacological hypotheses for gait disorders in Parkinson’s disease.

Authors: Devos, David Defebvre, L. Bordet, R.

Source: Fundamental & Clinical Pharmacology. Aug2010, Vol. 24 Issue 4, p407-421. 15p. 3 Diagrams, 1 Chart.

One‐Year Substantia Nigra R2*$$ {\mathrm{R}}_2^{\ast } $$ Changes across Parkinson's Disease Stages.

Authors: Coussediere, Calvin Pereira, Bruno Devos, David et al.

Source: Movement Disorders. Apr2026, p1. 16p. 3 Illustrations.

Real estate and ESG: poised to move the needle.

Authors: Gordon, Jacques DeVos, David

Source: IPE Real Assets. Jan/Feb2022, p12-13. 2p.

Seven Solutions for Neuroprotection in Parkinson's Disease.

Authors: Devos, David Hirsch, Etienne Wyse, Richard

Source: Movement Disorders. Feb2021, Vol. 36 Issue 2, p306-316. 11p.

Effectiveness of Continuous Dopaminergic Therapies in Parkinson's Disease: A Review of L-DOPA Pharmacokinetics/Pharmacodynamics.

Authors: Demailly, Alexandre Moreau, Caroline Devos, David

Source: Journal of Parkinson's Disease. 2024, Vol. 14 Issue 5, p925-939. 15p.

Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.

Authors: Devos, David Cabantchik, Z. Ioav Moreau, Caroline et al.

Source: Journal of Neural Transmission. Feb2020, Vol. 127 Issue 2, p189-203. 15p.

Feature selection using metaheuristics to predict annual amyotrophic lateral sclerosis progression.

Authors: Anani, Thibault Pradat-Peyre, Jean-François Delbot, François et al.

Source: Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. Feb2026, Vol. 27 Issue 1/2, p62-77. 16p.